Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients

in European Journal of Endocrinology

Abstract

The journal apologises for an error in the footnote to table 3 of this article published in the November issue of the European Journal of Endocrinology (vol 167, iss 5, pp 651–662). In the footnote, the information relating to the clinical details of patients should read as:

aClinical details on patients 1 and 3 have been reported in references (40, 42) respectively. and not as published

References

40 Petrossians P, de Herder W, Kwekkeboom D, Lamberigts G, Stevenaert A & Beckers A. Malignant prolactinoma discovered by D2 receptor imaging. Journal of Clinical Endocrinology and Metabolism 2000 85 398–401. (doi:10.1210/jc.85.1.398)

42 Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, François P, Jouanneau E, Passagia JG, Bernier M, Cornélius A, Figarella-Branger D, Trouillas J, Borson-Chazot F & Brue T. Temozolomide treatment in aggressive pituitary tumors and pituitarycarcinomas: a Frenchmulticenter experience. Journal of Clinical Endocrinology and Metabolism 2010 95 4592–4599. (doi:10.1210/jc.2010-0644)

If the inline PDF is not rendering correctly, you can download the PDF file here.